REGULATORY INFORMATION
Device Classification in Korea.
Under Annex 1 of the Enforcement Rule of Korea's Medical Devices Act, devices are divided into four risk classes. The review authority and technical documentation review period vary by classification.
Class 1
- Definition: Devices with minimal potential risk
- Examples: Manual wheelchairs, examination lights, vision charts and examination gloves
- Technical documentation review body: National Institute of Medical Device Safety Information (NIDS)
- Technical documentation review period: 5 business days
- Technical documentation review fee: KRW 85,000
Class 2
- Definition: Devices with low potential risk
- Examples: Syringes, patient monitors, powered wheelchairs, low-frequency stimulators and surgical gloves
- Technical documentation review bodies: MFDS-designated bodies (KTL, KTR, KCL, KTC, etc.)
- Technical documentation review period: 25 business days for initial review; 15 business days for changes
- Technical documentation review fee: KRW 2,400,000 for initial review; KRW 1,800,000 for changes
Class 3
- Definition: Devices with moderate potential risk
- Examples: Joint prostheses, CT scanners, dental implants, ventilators, peritoneal dialysis equipment and fluoroscopy systems
- Technical documentation review authority: Ministry of Food and Drug Safety (MFDS), Korea
- Technical documentation review period: 55 business days without clinical trial data; 70 business days with clinical trial data
- Technical documentation review fee: KRW 561,000 without clinical trial data; KRW 1,338,000 with clinical trial data
Class 4
- Definition: Devices with high potential risk
- Examples: Breast implants, pacemakers, cardiopulmonary bypass systems, tissue repair biomaterials and vascular grafts
- Technical documentation review authority: Ministry of Food and Drug Safety (MFDS), Korea
- Technical documentation review period: 55 business days without clinical trial data; 70 business days with clinical trial data
- Technical documentation review fee: KRW 561,000 without clinical trial data; KRW 1,338,000 with clinical trial data
PATH TO SUCCESSNeed expert support?
Contact Us